Drug Trial News

RSS

Achilles tendon injections offer no meaningful benefit over placebo

Commonly used injections for Achilles tendinopathy - pain, stiffness and swelling in the Achilles tendon - offer no meaningful clinical advantage over placebo (sham) treatment, finds a clinical trial published by The BMJ today.

28 Oct 2026

Targeted drug combination extends survival in advanced kidney cancer

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer.

28 Oct 2026

Black Dog Institute announces Australian-first ketamine treatment trial for Australia’s emergency service workers

Black Dog Institute has today announced a new clinical trial investigating whether ketamine, combined with evidence-based psychological therapy, can improve treatment outcomes for Australia's emergency service workers living with post-traumatic stress disorder (PTSD).

27 Oct 2026

New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a phase 1 trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.

26 Oct 2026

Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study, which was presented by Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on Oct. 24.

26 Oct 2026

New drug effectively decreases recurrence of and death from endometrial cancer

A new drug is effective at decreasing recurrence of and death from endometrial cancer, a landmark international study shows.

26 Oct 2026

Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.

24 Oct 2026

Abiraterone triplet therapy improves long-term survival in metastatic prostate cancer

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification.

24 Oct 2026

Drug combination delivers promising survival gains in advanced endometrial cancer

An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

24 Oct 2026

Kidney Week 2026 features late-breaking clinical trials in kidney care

The American Society of Nephrology, has selected the following late breaking clinical trials to be presented in-person at Kidney Week 2026 October 22–25.

24 Oct 2026

Novel immunosuppressant improves kidney function and quality of life after transplantation

The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant.

23 Oct 2026

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.

23 Oct 2026

Targeted drug extends survival across diverse pancreatic cancer patient groups

A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.

23 Oct 2026

Potassium binder helps dialysis patients manage dietary restrictions

Dietary potassium restriction is important for managing hyperkalemia, or high blood potassium levels, in individuals on maintenance hemodialysis, but it imposes a substantial day-to-day burden.

22 Oct 2026

Clinical trial establishes effective HIV dosing regimen for full-term newborns

An international study conducted through the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network including researchers at the University of California San Diego helped inform the U.S. Food and Drug Administration's (FDA) recent approval of dolutegravir, a second-generation integrase inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in newborns from birth.

22 Oct 2026

Modus Therapeutics: SEVUSMART study of sevuparin in children with severe malaria published in Nature Communications

Modus Therapeutics Holding AB (publ) announces that the manuscript based on the Phase Ib study SEVUSMART in severe malaria, lead-authored by Professor Kathryn Maitland of Imperial College London with co-authors from the SMAART consortium including members such as University College London and the University of Oxford, has been published today in the peer-reviewed journal Nature Communications, following independent peer review.

22 Oct 2026

ECOG-ACRIN opens trial testing ivonescimab for aggressive bile duct cancer

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it will open a randomized, registration-enabling phase 2/3 clinical trial to evaluate ivonescimab combined with chemotherapy as first-line treatment for patients with advanced biliary tract cancer (BTC).

21 Oct 2026

Blood test could slash sepsis antibiotics

A simple daily blood test could help critically ill sepsis patients come off antibiotics sooner, potentially reducing drug overuse and helping tackle the growing threat of antibiotic resistance, new research shows.

20 Oct 2026

First patient dosed in Phase 1 clinical trial of new cancer drug

On August 18, 2026, in Japan, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital, led by Professor Toshio SHIMIZU, administered DS1025 to the first patient worldwide as part of a global, multicenter First-in-Human Phase 1 clinical trial sponsored by Daiichi Sankyo.

19 Oct 2026

Blood Cancer United awards grant to diversify clinical trial access

Blood Cancer United, formerly The Leukemia & Lymphoma Society, has awarded $2.5 million to a research team led by Melissa Beauchemin, Ph.D., Assistant Professor at Columbia University School of Nursing, through its Equity in Access Research Program.

15 Oct 2026

1
2
3
4
...
1176
Next

Drug Trial News

Achilles tendon injections offer no meaningful benefit over placebo

Targeted drug combination extends survival in advanced kidney cancer

Black Dog Institute announces Australian-first ketamine treatment trial for Australia’s emergency service workers

New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer

Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

New drug effectively decreases recurrence of and death from endometrial cancer

Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy

Abiraterone triplet therapy improves long-term survival in metastatic prostate cancer

Drug combination delivers promising survival gains in advanced endometrial cancer

Kidney Week 2026 features late-breaking clinical trials in kidney care

Novel immunosuppressant improves kidney function and quality of life after transplantation

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

Targeted drug extends survival across diverse pancreatic cancer patient groups

Potassium binder helps dialysis patients manage dietary restrictions

Clinical trial establishes effective HIV dosing regimen for full-term newborns

Modus Therapeutics: SEVUSMART study of sevuparin in children with severe malaria published in Nature Communications

ECOG-ACRIN opens trial testing ivonescimab for aggressive bile duct cancer

Blood test could slash sepsis antibiotics

First patient dosed in Phase 1 clinical trial of new cancer drug

Blood Cancer United awards grant to diversify clinical trial access

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News